BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, Favier B, Galy G, Blay JY, Guastalla JP. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer. 2009;9:118-121. [PMID: 19433393 DOI: 10.3816/cbc.2009.n.021] [Cited by in Crossref: 45] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Linnert M, Iversen HK, Gehl J. Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol 2012;46:271-8. [PMID: 23412694 DOI: 10.2478/v10019-012-0042-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
2 Di Nunno V, Franceschi E, Tosoni A, Mura A, Minichillo S, Di Battista M, Gatto L, Maggio I, Lodi R, Bartolini S, Brandes AA. Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? Clin Drug Investig 2021;41:757-73. [PMID: 34403132 DOI: 10.1007/s40261-021-01070-1] [Reference Citation Analysis]
3 De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100:443-7. [PMID: 20440540 DOI: 10.1007/s11060-010-0200-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
4 Barresi V, Branca G, Caffo M, Caltabiano R, Ieni A, Vitarelli E, Lanzafame S, Tuccari G. Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy? Int J Mol Sci 2014;15:5663-79. [PMID: 24699047 DOI: 10.3390/ijms15045663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Brastianos HC, Cahill DP, Brastianos PK. Systemic therapy of brain metastases. Curr Neurol Neurosci Rep 2015;15:518. [PMID: 25492479 DOI: 10.1007/s11910-014-0518-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
6 Bohn KA, Adkins CE, Nounou MI, Lockman PR. Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden. Front Pharmacol 2017;8:193. [PMID: 28443023 DOI: 10.3389/fphar.2017.00193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
7 Gil-Gil MJ, Martinez-Garcia M, Sierra A, Conesa G, Del Barco S, González-Jimenez S, Villà S. Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clin Transl Oncol 2014;16:436-46. [PMID: 24277572 DOI: 10.1007/s12094-013-1110-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
8 Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12:1109-17. [PMID: 21992853 DOI: 10.1016/S1470-2045(11)70244-3] [Cited by in Crossref: 70] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
9 Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013;137:1-12. [PMID: 23143215 DOI: 10.1007/s10549-012-2328-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
10 Bachelot T, Le Rhun E, Labidi-Gally I, Heudel P, Gilabert M, Bonneterre J, Pierga JY, Gonçalves A. [Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies]. Bull Cancer 2013;100:7-14. [PMID: 23305997 DOI: 10.1684/bdc.2012.1676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
11 Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276. [PMID: 24353011 DOI: 10.1007/s11940-013-0276-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
12 Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. Cancer Treat Rev 2021;103:102324. [PMID: 34953200 DOI: 10.1016/j.ctrv.2021.102324] [Reference Citation Analysis]
13 Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC. Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Rep Oncol 2015;8:72-7. [PMID: 25848355 DOI: 10.1159/000375293] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
14 Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Sasaki T, Takeno S, Yamashita Y. Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer. Case Rep Oncol 2014;7:117-21. [PMID: 24707258 DOI: 10.1159/000360132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti M, Nolan RL, Lockman PR. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res 2018;132:47-68. [PMID: 29604436 DOI: 10.1016/j.phrs.2018.03.021] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 12.3] [Reference Citation Analysis]
16 Yamamoto D, Iwase S, Tsubota Y, Sueoka N, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y. Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. Onco Targets Ther 2012;5:185-9. [PMID: 23049262 DOI: 10.2147/OTT.S36515] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
17 Berghoff AS, Preusser M. Anti-angiogenic therapies in brain metastases. Memo. 2018;11:14-17. [PMID: 29606977 DOI: 10.1007/s12254-018-0384-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
18 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmgenomics Pers Med 2010;3:79-85. [PMID: 23226044 DOI: 10.2147/pgpm.s7940] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
20 Bailleux C, Eberst L, Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer 2021;124:142-55. [PMID: 33250512 DOI: 10.1038/s41416-020-01175-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Foster CH, Dave P, Sherman JH. Chemotherapy for the Management of Cerebral Metastases. Neurosurg Clin N Am 2020;31:603-11. [PMID: 32921355 DOI: 10.1016/j.nec.2020.06.009] [Reference Citation Analysis]